New anti-fungal compounds 1PB1 and 45R from Streptomyces chrestomyceticus ADP4 target exo-β-1,3-glucanase and ergosterol biosynthesis in Candida albicans.
The results suggested that the compounds, 1PB1 and 45R, possessed a dual mode of action involving two cellular targets: CYP51 and exo-β-1,3-glucanase in Candida albicans.